Plasma sCD28, sCTLA-4 levels in neuromyelitis optica and multiple sclerosis during relapse

BackgroundSoluble forms of CD28 (sCD28) and CTLA-4 (sCTLA-4) were associated with many autoimmune diseases like Sjögren's syndrome, systemic lupus erythematosus, asthma, and autoimmune myasthenia gravis. However, sCD28 and sCTLA-4 in neuromyelitis optica (NMO) and multiple sclerosis (MS) patients were less studied.ObjectiveTo measure the plasma sCD28, sCTLA-4 in NMO and MS patients, and investigate whether sCD28 and sCTLA-4 possible use as sensitive biomarkers for diseases activity.MethodsPlasma concentrations of sCD28, sCTLA-4 were measured by an enzyme-linked immunosorbent assay (ELISA) in NMO (n = 22), MS (n = 21) patients and controls (n = 18).ResultsThe concentration of sCD28 levels were higher in the inflammatory demyelinating diseases cohort compared with the controls (NMO, p = 0.034; MS, p = 0.026) and the levels of sCD28 were slightly higher in NMO compared with MS. The sCTLA-4 levels were lower in the MS subgroup compared with the controls (p = 0.032). Both sCD28 and sCTLA-4 did not show any correlation with EDSS score in NMO and MS patients.ConclusionsOur study revealed for the first time that the levels of increased plasma sCD28 and decreased plasma sCTLA-4 in NMO and MS patients, but had little correlation with clinical presentations.